Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Rdmd Secures $3M In Seed Funding To Drive Patient-accelerated Drug Development In Rare Diseases | Business Wire
Venture Capital

Rdmd Secures $3M In Seed Funding To Drive Patient-accelerated Drug Development In Rare Diseases | Business Wire

by businesswire.com posted 2months ago 544 views
SAN FRANCISCO--(BUSINESS WIRE)--RDMD, a healthcare technology company dedicated to accelerating research for patients with rare diseases, today announced that it has raised $3 million in seed financing. The financing was led by Lux Capital, with participation from Village Global, First Round's Healthcare Co-Op, Garuda, Shasta Ventures and various angel investors from the biotech and healthtech industry. RDMD has developed a technology platform that generates deep data insights to accelerate rar.